NYSE:IQV - Iqvia Stock Price, Price Target & More

$97.27 -0.80 (-0.82 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$97.27
Today's Range$97.02 - $98.45
52-Week Range$81.43 - $110.67
Volume602,628 shs
Average Volume867,562 shs
Market Capitalization$20.43 billion
P/E Ratio22.31
Dividend YieldN/A
Beta0.63

About Iqvia (NYSE:IQV)

Iqvia logoIQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone919-998-2000

Debt

Debt-to-Equity Ratio1.21%
Current Ratio1.19%
Quick Ratio1.19%

Price-To-Earnings

Trailing P/E Ratio22.31
Forward P/E Ratio19.38
P/E Growth1.67

Sales & Book Value

Annual Sales$9.74 billion
Price / Sales2.08
Cash Flow$9.6979 per share
Price / Cash10.03
Book Value$40.19 per share
Price / Book2.42

Profitability

EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.44%
Return on Equity13.03%
Return on Assets4.65%

Miscellaneous

Employees55,000
Outstanding Shares208,270,000

How to Become a New Pot Stock Millionaire

Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings data on Wednesday, February, 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.34 by $0.02. The medical research company had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The company's revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.09 earnings per share. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Iqvia.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of $5.35-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.34. The company issued revenue guidance of $8.45-8.65 billion, compared to the consensus revenue estimate of $8.53 billion.Iqvia also updated its Q1 guidance to $1.23-1.30 EPS.

What price target have analysts set for IQV?

17 brokerages have issued 12-month target prices for Iqvia's shares. Their forecasts range from $93.42 to $128.00. On average, they expect Iqvia's share price to reach $110.3776 in the next twelve months. View Analyst Ratings for Iqvia.

Who are some of Iqvia's key competitors?

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Ari Bousbib, Chairman of the Board, President, Chief Executive Officer (Age 56)
  • Michael R. McDonnell, Chief Financial Officer, Executive Vice President (Age 53)
  • Kevin C. Knightly, President - Information and Technology Solutions (Age 55)
  • W. Richard Staub III, President - Research and Development Solutions (Age 54)
  • Erlinger M. Sherbet, Executive Vice President, General Counsel, Secretary (Age 52)
  • Dennis B. Gillings Ph.D., Lead Director (Age 72)
  • John P. Connaughton, Independent Director (Age 54)
  • Jonathan J. Coslet, Independent Director (Age 52)
  • John G. Danhakl, Independent Director (Age 60)
  • Michael J. Evanisko, Independent Director (Age 67)

Has Iqvia been receiving favorable news coverage?

Media coverage about IQV stock has trended positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iqvia earned a news sentiment score of 0.29 on Accern's scale. They also gave headlines about the medical research company an impact score of 45.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $97.27.

How big of a company is Iqvia?

Iqvia has a market capitalization of $20.43 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  319 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Iqvia (NYSE:IQV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for Iqvia in the last 12 months. Their average twelve-month price target is $110.3776, suggesting that the stock has a possible upside of 13.48%. The high price target for IQV is $128.00 and the low price target for IQV is $93.42. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.652.592.47
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $110.3776$109.9071$107.5263$93.6424
Price Target Upside: 13.48% upside9.19% upside7.29% upside6.22% downside

Iqvia (NYSE:IQV) Consensus Price Target History

Price Target History for Iqvia (NYSE:IQV)

Iqvia (NYSE:IQV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Goldman SachsUpgradeNeutral -> BuyMediumView Rating Details
4/9/2018ArgusBoost Price TargetBuy -> Buy$110.00 -> $112.00LowView Rating Details
3/7/2018SunTrust BanksUpgradeHold -> BuyLowView Rating Details
2/15/2018Royal Bank of CanadaSet Price TargetBuy$118.00LowView Rating Details
2/15/2018Piper JaffrayReiterated RatingHold$103.00LowView Rating Details
2/15/2018JPMorgan ChaseBoost Price TargetOverweight$115.00 -> $120.00LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$97.00LowView Rating Details
1/18/2018Evercore ISIInitiated CoverageOutperform -> Outperform$112.00HighView Rating Details
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$112.00LowView Rating Details
11/10/2017KeyCorpReiterated RatingOverweight -> Sector Weight$100.00N/AView Rating Details
11/9/2017Morgan StanleyBoost Price TargetOverweight$96.00 -> $121.00N/AView Rating Details
10/31/2017Credit Suisse GroupReiterated RatingOutperform$115.00 -> $125.00N/AView Rating Details
10/30/2017Jefferies GroupBoost Price TargetHold$107.00 -> $110.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetOverweight$100.00 -> $120.00N/AView Rating Details
10/27/2017Stifel NicolausUpgradeHold -> Buy$92.00 -> $128.00N/AView Rating Details
10/9/2017Robert W. BairdReiterated RatingHold$98.00N/AView Rating Details
8/7/2017CitigroupBoost Price TargetNeutral$96.00 -> $97.00LowView Rating Details
8/4/2017William BlairUpgradeMarket Perform -> Outperform$70.10 -> $93.42LowView Rating Details
2/17/2017Wells FargoUpgradeMarket Perform -> OutperformN/AView Rating Details
2/3/2017Deutsche BankDowngradeBuy -> Hold$81.00 -> $80.00N/AView Rating Details
12/4/2016Pacific CrestSet Price TargetBuy$82.00N/AView Rating Details
12/2/2016Bank of AmericaDowngradeBuy -> Neutral$89.00N/AView Rating Details
12/1/2016Raymond JamesReiterated RatingStrong-Buy -> Market PerformN/AView Rating Details
10/5/2016UBSReiterated RatingBuy$78.00 -> $90.00N/AView Rating Details
7/11/2016Avondale PartnersUpgradeMarket Perform -> Outperform$62.00 -> $87.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Iqvia (NYSE:IQV) Earnings History and Estimates Chart

Earnings by Quarter for Iqvia (NYSE:IQV)

Iqvia (NYSE:IQV) Earnings Estimates

2018 EPS Consensus Estimate: $4.49
2019 EPS Consensus Estimate: $6.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.69$1.33$1.01
Q2 20183$0.71$1.33$1.10
Q3 20182$0.79$1.35$1.07
Q4 20183$0.94$1.54$1.31
Q1 20191$1.36$1.36$1.36
Q2 20191$1.49$1.49$1.49
Q3 20191$1.59$1.59$1.59
Q4 20191$1.76$1.76$1.76

Iqvia (NYSE IQV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$1.20N/AView Earnings Details
2/14/2018Q4 2017$1.34$1.32$2.1380 billion$2.1610 billionViewN/AView Earnings Details
10/26/2017Q3 2017$1.14$1.19$2.0147 billion$2.0190 billionViewN/AView Earnings Details
8/3/2017Q2 2017$1.05$1.09$1.9601 billion$1.9690 billionViewListenView Earnings Details
5/3/2017Q1 17$0.95$1.01$1.9108 billion$1.9110 billionViewListenView Earnings Details
2/14/2017Q416$1.05$1.09$1.97 billion$1.9530 billionViewListenView Earnings Details
11/2/2016Q316$0.99$1.00$1.16 billion$1.14 billionViewN/AView Earnings Details
7/27/2016Q216$0.90$0.93$1.15 billion$1.17 billionViewListenView Earnings Details
5/3/2016Q116$0.86$0.89$1.12 billion$1.11 billionViewN/AView Earnings Details
2/11/2016Q415$0.87$0.90$1.13 billion$1.13 billionViewListenView Earnings Details
10/28/2015Q315$0.81$0.94$1.11 billion$1.09 billionViewListenView Earnings Details
7/29/2015Q215$0.70$0.78$1.05 billion$1.07 billionViewListenView Earnings Details
4/29/2015Q115$0.71$0.72$1.04 billion$1.35 billionViewN/AView Earnings Details
2/12/2015Q414$0.67$0.71$1.08 billion$1.06 billionViewN/AView Earnings Details
10/30/2014Q214$0.64$0.65$1.05 billion$1.06 billionViewN/AView Earnings Details
7/31/2014Q2$0.60$0.65$1.0301 billion$1.0350 billionViewN/AView Earnings Details
5/2/2014Q114$0.55$0.68$1.02 billion$1,000.00 millionViewN/AView Earnings Details
2/19/2014Q413$0.55$0.58$980.64 million$1.38 millionViewN/AView Earnings Details
10/31/2013Q313$0.50$0.54$952.14 million$1.20 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.46$0.50$942.30 million$1.30 billionViewN/AView Earnings Details
2/15/2011$0.10$0.12ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Iqvia (NYSE:IQV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Iqvia (NYSE IQV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 92.35%
Insider Trading History for Iqvia (NYSE:IQV)
Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Iqvia (NYSE IQV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Michael J EvaniskoDirectorSell815$100.00$81,500.00View SEC Filing  
3/15/2018Robert ParksInsiderSell896$105.73$94,734.08View SEC Filing  
3/5/2018Michael J EvaniskoDirectorSell816$100.00$81,600.00View SEC Filing  
2/26/2018James H Erlinger IIIInsiderSell10,000$100.00$1,000,000.00View SEC Filing  
1/17/2018James H Erlinger IIIInsiderSell10,000$99.97$999,700.00View SEC Filing  
12/20/2017James H Erlinger IIIInsiderSell10,000$101.21$1,012,100.00View SEC Filing  
12/1/2017Ari BousbibInsiderSell46,080$101.79$4,690,483.20View SEC Filing  
11/30/2017Cpp Investment Board Private HMajor ShareholderSell7,497,807$102.00$764,776,314.00View SEC Filing  
11/30/2017John ConnaughtonDirectorSell1,163,191$102.00$118,645,482.00View SEC Filing  
11/6/2017Jack M GreenbergDirectorSell33,400$108.07$3,609,538.00View SEC Filing  
11/1/2017Ari BousbibInsiderSell46,080$108.14$4,983,091.201,036,839View SEC Filing  
10/18/2017James H Erlinger IIIInsiderSell10,000$100.51$1,005,100.0027,340View SEC Filing  
10/2/2017Ari BousbibInsiderSell46,080$94.91$4,373,452.801,036,839View SEC Filing  
9/27/2017James H Erlinger IIIInsiderSell10,000$94.52$945,200.0027,340View SEC Filing  
9/19/2017Cpp Investment Board Private HMajor ShareholderSell6,748,026$94.87$640,185,226.62View SEC Filing  
9/19/2017John ConnaughtonDirectorSell1,030,429$94.87$97,756,799.23View SEC Filing  
9/1/2017Ari BousbibInsiderSell46,080$95.65$4,407,552.001,036,839View SEC Filing  
8/28/2017Cpp Investment Board Private HMajor ShareholderSell5,218,245$97.33$507,891,785.85View SEC Filing  
8/28/2017Dennis B Ph D GillingsDirectorSell968,023$97.33$94,217,678.599,071,839View SEC Filing  
8/25/2017Kevin C KnightlyInsiderSell19,339$99.51$1,924,423.8940,650View SEC Filing  
8/9/2017Kevin C KnightlyInsiderSell20,000$90.28$1,805,600.0046,826View SEC Filing  
8/7/2017Ari BousbibInsiderSell92,160$90.35$8,326,656.001,082,919View SEC Filing  
5/31/2017Cpp Investment Board Private HMajor ShareholderSell7,131,165$84.01$599,089,171.65View SEC Filing  
5/31/2017Dennis B Ph D GillingsDirectorSell860,000$84.01$72,248,600.0010,002,230View SEC Filing  
5/30/2017John G DanhaklDirectorSell761,143$84.01$63,943,623.43View SEC Filing  
5/17/2017Jack M GreenbergDirectorSell6,092$82.50$502,590.002,930View SEC Filing  
11/21/2016Jack M GreenbergDirectorSell2,000$79.77$159,540.002,930View SEC Filing  
6/9/2016Kevin K GordonCOOSell24,000$66.41$1,593,840.0041,899View SEC Filing  
6/7/2016Corp 3IMajor ShareholderSell2,250,000$66.10$148,725,000.00View SEC Filing  
5/12/2016Annie H LoDirectorBuy502$64.80$32,529.602,062View SEC Filing  
5/10/2016Kevin K GordonCOOSell24,000$67.42$1,618,080.0041,899View SEC Filing  
4/12/2016Kevin K GordonCOOSell24,000$69.44$1,666,560.0041,899View SEC Filing  
3/22/2016Kevin K GordonCOOSell3,639$65.01$236,571.3921,538View SEC Filing  
3/18/2016Kevin K GordonCOOSell20,361$65.01$1,323,668.6119,950View SEC Filing  
3/1/2016Kevin K. GordonCOOSell24,000$65.03$1,560,720.0041,899View SEC Filing  
9/2/2015Charles Edward WilliamsSVPSell5,000$72.43$362,150.002,071View SEC Filing  
5/19/2015Dennis B Ph D GillingsMajor ShareholderSell2,503,123$64.85$162,327,526.55View SEC Filing  
5/19/2015Tpg Advisors V, Inc.InsiderSell2,251,719$64.85$146,023,977.15View SEC Filing  
3/25/2015Michael J EvaniskoDirectorSell2,500$67.10$167,750.00View SEC Filing  
2/2/2015Kevin K GordonCFOSell25,000$60.19$1,504,750.00View SEC Filing  
1/7/2015Michael J EvaniskoDirectorSell2,500$57.86$144,650.00View SEC Filing  
1/2/2015Kevin K GordonCFOSell25,000$59.16$1,479,000.00View SEC Filing  
12/11/2014Jack M GreenbergDirectorSell23,508$57.29$1,346,773.32View SEC Filing  
12/1/2014Kevin K GordonCFOSell25,000$56.77$1,419,250.00View SEC Filing  
11/10/2014Dennis B Ph D GillingsMajor ShareholderSell3,566,187$58.09$207,159,802.83View SEC Filing  
11/7/2014Michael J EvaniskoDirectorSell2,500$57.50$143,750.00View SEC Filing  
11/3/2014Kevin K GordonCFOSell25,000$59.00$1,475,000.00View SEC Filing  
7/2/2014Michael J EvaniskoDirectorSell5,000$54.00$270,000.00View SEC Filing  
5/27/2014Tpg Advisors Iii, Inc.Major ShareholderSell3,287,209$50.23$165,116,508.07View SEC Filing  
3/26/2014Christopher GordonDirectorSell570,682$50.31$28,711,011.42View SEC Filing  
3/26/2014Dennis Ph Gillingsmajor shareholderSell570,681$50.31$28,710,961.1116,609,827View SEC Filing  
3/18/2014Mireille Phd GillingsDirectorSell3,304,542$50.31$166,251,508.02View SEC Filing  
3/18/2014Tpg Advisors Iii, Inc.major shareholderSell3,564,119$50.31$179,310,826.89View SEC Filing  
1/17/2014Derek WinstanlyVPSell60,000$50.00$3,000,000.00229,500View SEC Filing  
1/16/2014Michael EvaniskoDirectorSell5,000$50.00$250,000.0015,400View SEC Filing  
1/10/2014Derek WinstanlyVPSell60,000$48.00$2,880,000.00229,500View SEC Filing  
12/20/2013Derek WinstanlyVPSell60,000$46.00$2,760,000.00229,500View SEC Filing  
12/10/2013Derek WinstanlyVPSell60,000$44.00$2,640,000.00229,500View SEC Filing  
11/20/2013Michael EvaniskoDirectorSell8,000$43.00$344,000.0020,400View SEC Filing  
11/18/2013John RatliffCOOSell212,140$42.55$9,026,557.00View SEC Filing  
11/18/2013Michael MortimerVPSell200,000$42.55$8,510,000.0025,000View SEC Filing  
5/14/2013Group Holdings (Sbs) Advis TpgMajor ShareholderSell3,944,899$37.80$149,117,182.20View SEC Filing  
5/14/2013Mireille GillingsDirectorSell2,257,805$37.80$85,345,029.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Iqvia (NYSE IQV) News Headlines

Source:
DateHeadline
EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi ArabiaEARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia
finance.yahoo.com - April 21 at 4:41 PM
Insider Selling: Iqvia Holdings Inc (IQV) Director Sells 815 Shares of StockInsider Selling: Iqvia Holdings Inc (IQV) Director Sells 815 Shares of Stock
www.americanbankingnews.com - April 20 at 7:40 PM
Prescriptions of the drugs that fueled the overdose crisis are dropping around the USPrescriptions of the drugs that fueled the overdose crisis are dropping around the US
www.businessinsider.com - April 19 at 9:09 AM
IQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 YearsIQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 Years
finance.yahoo.com - April 19 at 9:09 AM
Iqvia Holdings Inc (IQV) Given Average Rating of "Buy" by AnalystsIqvia Holdings Inc (IQV) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 5:17 PM
IQVIA to Announce First-Quarter 2018 Results on May 2, 2018IQVIA to Announce First-Quarter 2018 Results on May 2, 2018
finance.yahoo.com - April 18 at 4:56 PM
Iqvia (IQV) Upgraded at Zacks Investment ResearchIqvia (IQV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:46 AM
$2.44 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter$2.44 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter
www.americanbankingnews.com - April 16 at 1:56 AM
Zacks: Analysts Expect Iqvia Holdings Inc (IQV) to Post $1.28 EPSZacks: Analysts Expect Iqvia Holdings Inc (IQV) to Post $1.28 EPS
www.americanbankingnews.com - April 14 at 11:20 PM
Reviewing EXACT Sciences (EXAS) and Iqvia (IQV)Reviewing EXACT Sciences (EXAS) and Iqvia (IQV)
www.americanbankingnews.com - April 14 at 5:27 PM
Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2%Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2%
seekingalpha.com - April 13 at 4:43 PM
Goldman Sachs Upgrades Iqvia (IQV) to "Buy"Goldman Sachs Upgrades Iqvia (IQV) to "Buy"
www.americanbankingnews.com - April 13 at 10:37 AM
Financial Review: Iqvia (IQV) & Exelixis (EXEL)Financial Review: Iqvia (IQV) & Exelixis (EXEL)
www.americanbankingnews.com - April 12 at 5:27 PM
Dennis Gillings retires from Iqvias board of directorsDennis Gillings retires from Iqvia's board of directors
www.bizjournals.com - April 12 at 4:43 PM
Does IQVIA Holdings Inc’s (NYSE:IQV) PE Ratio Signal A Buying Opportunity?Does IQVIA Holdings Inc’s (NYSE:IQV) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - April 12 at 4:43 PM
Dennis Gillings retires from Iqvia’s board of directorsDennis Gillings retires from Iqvia’s board of directors
finance.yahoo.com - April 12 at 4:43 PM
Argus Raises Iqvia (IQV) Price Target to $112.00Argus Raises Iqvia (IQV) Price Target to $112.00
www.americanbankingnews.com - April 9 at 11:02 AM
Zacks Investment Research Lowers Iqvia (IQV) to HoldZacks Investment Research Lowers Iqvia (IQV) to Hold
www.americanbankingnews.com - April 5 at 4:38 PM
Iqvia (IQV) Price Target Raised to $110.00 at Jefferies GroupIqvia (IQV) Price Target Raised to $110.00 at Jefferies Group
www.americanbankingnews.com - April 4 at 1:20 PM
Iqvia (IQV) Downgraded by ValuEngineIqvia (IQV) Downgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM
Zacks Investment Research Upgrades Iqvia (IQV) to BuyZacks Investment Research Upgrades Iqvia (IQV) to Buy
www.americanbankingnews.com - April 3 at 9:19 PM
From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
finance.yahoo.com - April 3 at 4:43 PM
Iqvias (IQV) "Outperform" Rating Reaffirmed at Credit Suisse GroupIqvia's (IQV) "Outperform" Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - April 2 at 8:05 PM
Iqvia (IQV) Downgraded to "Hold" at Zacks Investment ResearchIqvia (IQV) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 9:48 PM
We took 65% more antibiotics in 2015 than we did in 2000We took 65% more antibiotics in 2015 than we did in 2000
www.msn.com - March 27 at 4:34 PM
Iqvia (IQV) Rating Increased to Buy at Zacks Investment ResearchIqvia (IQV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:17 PM
Iqvia (IQV) Lowered to "Sell" at Zacks Investment ResearchIqvia (IQV) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 25 at 11:05 AM
Iqvia Holdings Inc (IQV) Receives Consensus Recommendation of "Buy" from AnalystsIqvia Holdings Inc (IQV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 5:42 PM
Iqvia (IQV) Stock Rating Upgraded by Zacks Investment ResearchIqvia (IQV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 9:02 PM
Active-Investors: Free Research Report as IQVIAs Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-YActive-Investors: Free Research Report as IQVIA's Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-Y
www.finanznachrichten.de - March 23 at 9:09 AM
Free Research Report as IQVIA’s Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-YFree Research Report as IQVIA’s Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-Y
finance.yahoo.com - March 23 at 9:09 AM
Robert Parks Sells 896 Shares of Iqvia Holdings Inc (IQV) StockRobert Parks Sells 896 Shares of Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 16 at 8:36 PM
IQVIA Establishes Alliance with MuleSoft to Deliver Innovative Integration Technology to Life Sciences CompaniesIQVIA Establishes Alliance with MuleSoft to Deliver Innovative Integration Technology to Life Sciences Companies
finance.yahoo.com - March 15 at 9:03 AM
Tillerson is Done...and so is the NASDAQs Winning StreakTillerson is Done...and so is the NASDAQ's Winning Streak
finance.yahoo.com - March 14 at 6:02 PM
Tillerson is Done...and so is the NASDAQ's Winning StreakTillerson is Done...and so is the NASDAQ's Winning Streak
finance.yahoo.com - March 14 at 10:06 AM
IQVIA Forms Alliance with Box to Provide Revolutionary, Cloud-Based Content Management Solutions to the Life Sciences and Healthcare IndustriesIQVIA Forms Alliance with Box to Provide Revolutionary, Cloud-Based Content Management Solutions to the Life Sciences and Healthcare Industries
finance.yahoo.com - March 14 at 10:06 AM
IQVIA Institute for Human Data Science Study: 10 Predictions for Innovation, Spending Drivers and Societal Value of Medicines that Will Transform Global Healthcare in 2018 and BeyondIQVIA Institute for Human Data Science Study: 10 Predictions for Innovation, Spending Drivers and Societal Value of Medicines that Will Transform Global Healthcare in 2018 and Beyond
finance.yahoo.com - March 13 at 9:27 AM
Iqvia Holdings Inc (IQV) Expected to Post Earnings of $1.28 Per ShareIqvia Holdings Inc (IQV) Expected to Post Earnings of $1.28 Per Share
www.americanbankingnews.com - March 11 at 6:39 PM
Iqvia (IQV) Raised to "Buy" at SunTrust BanksIqvia (IQV) Raised to "Buy" at SunTrust Banks
www.americanbankingnews.com - March 11 at 1:48 PM
Biohaven Pharmaceutical (BHVN) versus Iqvia (IQV) Head-To-Head ReviewBiohaven Pharmaceutical (BHVN) versus Iqvia (IQV) Head-To-Head Review
www.americanbankingnews.com - March 11 at 6:02 AM
Iqvia Holdings Inc (IQV) Director Sells $81,600.00 in StockIqvia Holdings Inc (IQV) Director Sells $81,600.00 in Stock
www.americanbankingnews.com - March 7 at 7:30 PM
Technical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIA - PR Newswire (press release)Technical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIA - PR Newswire (press release)
www.prnewswire.com - March 7 at 9:19 AM
Stocks Fight Their Way Forward Amid Tariff ConcernsStocks Fight Their Way Forward Amid Tariff Concerns
finance.yahoo.com - March 7 at 9:19 AM
Steve Mandel Expands Reach in Health Care Space With Exact SciencesSteve Mandel Expands Reach in Health Care Space With Exact Sciences
finance.yahoo.com - March 6 at 5:00 PM
Standard Life Aberdeen plc Invests $2.65 Million in Iqvia Holdings Inc (IQV) StockStandard Life Aberdeen plc Invests $2.65 Million in Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 5 at 4:03 PM
Alliancebernstein L.P. Takes Position in Iqvia Holdings Inc (IQV)Alliancebernstein L.P. Takes Position in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 5 at 4:08 AM
American International Group Inc. Buys New Holdings in Iqvia Holdings Inc (IQV)American International Group Inc. Buys New Holdings in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 4 at 4:24 AM
Tiger Eye Capital LLC Invests $21.23 Million in Iqvia Holdings Inc (IQV) StockTiger Eye Capital LLC Invests $21.23 Million in Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 2 at 9:29 PM
Lazard Asset Management LLC Buys New Position in Iqvia Holdings Inc (IQV)Lazard Asset Management LLC Buys New Position in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 2 at 2:21 PM
15,699 Shares in Iqvia Holdings Inc (IQV) Purchased by First Republic Investment Management Inc.15,699 Shares in Iqvia Holdings Inc (IQV) Purchased by First Republic Investment Management Inc.
www.americanbankingnews.com - March 2 at 11:48 AM

SEC Filings

Iqvia (NYSE:IQV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Iqvia (NYSE:IQV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Iqvia (NYSE IQV) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.